论文部分内容阅读
在过去几十年里,免疫学家试图缩小动物肿瘤模型与人类肿瘤免疫研究之间的差异。最近发现,接受IL-2激活淋巴细胞和同种或异种肿瘤“疫苗”治疗的病人肿瘤消退,引起了对肿瘤疫苗研究的兴趣。另外,包括基因治疗在内的新技术能够在鼠肿瘤模型中增强抗肿瘤免疫效应。 人们试图认别免疫应答中作为靶抗原的肿瘤特异抗原或肿瘤相关抗原,Boon,Finn和其他研究者采用细胞毒性T细胞分别对MAGE1MUCI进行了分析研究,证明其为存在于多种人类肿瘤的肿瘤抗原。进一步的研究是利用病人血清,根据人体抗体识别多种肿瘤细胞成分,确定潜在的肿瘤抗原。Winter等建立了一系列肺癌细胞株(主要是小细胞肺癌),为研究相关肺肿瘤的细胞生物学和分子生物学提供了丰富
In the past few decades, immunologists have tried to reduce the differences between animal tumor models and human tumor immunological studies. Recently, it has been discovered that tumor regression in patients treated with IL-2 activated lymphocytes and “homogeneous or xenogeneic” vaccines has attracted interest in tumor vaccine research. In addition, new technologies, including gene therapy, can enhance anti-tumor immune effects in murine tumor models. People try to identify tumor-specific antigens or tumor-associated antigens as target antigens in the immune response. Boon, Finn, and other researchers used cytotoxic T cells to analyze MAGE1MUCI respectively, demonstrating that they are tumors that exist in many human tumors. antigen. Further research is to use the patient’s serum to identify a variety of tumor cell components based on human antibodies to identify potential tumor antigens. Winter et al. have established a series of lung cancer cell lines (mainly small cell lung cancer) that provide a wealth of insight into cell biology and molecular biology of related lung tumors.